Adial Pharmaceuticals Receives Final Reimbursement Payment From Adovate
Adial Pharmaceuticals Receives Final Reimbursement Payment From Adovate
CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that on December 16, 2023, it received the final development cost reimbursement payment of $350,000 from Adovate, LLC under the terms of the final asset purchase agreement (the "FAA") executed with Adovate for purchase of the assets and business of the Company's wholly owned subsidiary, Purnovate, Inc. Under the agreement, the Company is also eligible to receive up to approximately $11 million in development and approval milestones for each compound (up to $33 million in total development and approval milestones for the first three compounds alone), as well as a total of $50 million in additional commercial milestones, for a total consideration of up to $83 million with potential milestone payments on additional compounds. Additionally, the Company will receive a low, single-digit royalty and acquired a 15% equity stake in Adovate. The FAA also provides for anti-dilution protection from future Adovate equity raises in order to maintain at least 15% ownership in Adovate. The anti-dilution protection expires upon Adovate receiving $4,000,000 in cumulative funding.
弗吉尼亞州夏洛茨維爾,2023年12月20日(GLOBE NEWSWIRE)——專注於開發治療和預防成癮及相關疾病療法的臨床階段生物製藥公司Adial Pharmicals, Inc.(納斯達克股票代碼:ADIL;ADILW)(“Adial” 或 “公司”)今天宣佈,它於2023年12月16日收到了35萬美元的最終開發成本報銷款根據與Adovate簽訂的最終資產購買協議(“FAA”)的條款,Adovate, LLC收購公司全資資產和業務子公司Purnovate, Inc. 根據該協議,公司還有資格獲得每種化合物高達約1100萬美元的開發和批准里程碑(僅前三種化合物的總開發和批准里程碑就高達3,300萬美元),以及總額爲5000萬美元的額外商業里程碑,總對價高達8300萬美元,其他化合物的潛在里程碑付款。此外,該公司將獲得較低的個位數特許權使用費,並收購Adovate15%的股權。美國聯邦航空局還規定了反稀釋保護,使其免受未來Adovate股權籌集的影響,以維持Adovate至少15%的所有權。反稀釋保護將在Adovate獲得400萬美元的累積資金後到期。
About Adial Pharmaceuticals, Inc.
關於阿迪爾製藥公司
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at .
Adial Pharmicals是一家處於臨床階段的生物製藥公司,專注於開發治療和預防成癮及相關疾病的療法。該公司的主要研究性新藥產品AD04是一種具有基因靶向的血清素-3受體拮抗劑,是治療大量飲酒患者酒精使用障礙(AUD)的治療藥物,最近在該公司的關鍵3期臨床試驗中進行了研究,該試驗旨在對使用該公司專有的伴隨診斷基因測試確定的某些靶基因型(估計約佔澳元人群的三分之一)的受試者進行AUD的潛在治療。ONWARD在減少大量飲酒患者大量飲酒方面顯示出令人鼓舞的結果,並且沒有明顯的安全性或耐受性問題。AD04還被認爲有可能治療其他成癮性疾病,例如阿片類藥物使用障礙、賭博和肥胖。更多信息可在以下網址獲得: 。
Forward Looking Statements
前瞻性陳述
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the Company being eligible to receive total consideration of up to $83 million with potential milestone payments on additional compounds and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to maintain our Nasdaq listing, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to retain our key employees or maintain our Nasdaq listing, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
這個 溝通 包含 肯定的 “前瞻性 聲明” 之內 這 意思 的 這 美國 聯邦證券法。此類陳述基於各種事實,並利用許多重要假設得出。 和 是 主題 到 已知的 和 未知 風險, 不確定性 和 其他 因素 那個 可能 導致實際業績、業績或成就與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異。前面加上、後面或以其他方式包含 “相信”、“期望”、“預期”、“打算”、“項目”、“估計”、“計劃” 等類似表達方式或未來或條件動詞(例如 “將”、“應該”、“將”、“可能” 和 “可以”)的陳述本質上通常是前瞻性的,而不是歷史事實, 儘管 不 所有 前瞻的 聲明 包括 這 上述內容。 這個 前瞻的 聲明中包括關於公司有資格獲得高達8,300萬美元的總對價,並可能對其他化合物進行里程碑式付款的聲明,以及AD04有可能治療其他成癮性疾病,例如阿片類藥物使用障礙,賭博, 和 肥胖。 任意 前瞻的 聲明 包括在內 在這方面 反映 我們的 當前的 觀點, 和 它們涉及某些風險和不確定性,包括我們推行監管戰略的能力、維持納斯達克上市的能力、推進正在進行的合作討論的能力、我們獲得監管部門批准以實現候選產品商業化的能力或遵守持續的監管要求的能力, 我們開發戰略伙伴關係機會和保持合作的能力,我們獲得或維持爲研發活動提供資金所必需的資本或補助金的能力,我們留住關鍵員工或維持我們在納斯達克上市的能力, 我們能夠按時完成臨床試驗並達到預期的結果和收益,與我們推廣或商業化特定適應症候選產品的能力相關的監管限制,在市場上接受我們的候選產品以及成功開發、營銷或銷售我們的產品,我們維持許可協議的能力,專利財產的持續維護和增長,以及 我們的 能力 到 保留 我們的 鑰匙 僱員 要麼 保持 我們的 納斯達 清單。 這些 風險 不應該 是 解釋 如同 詳盡無遺 和 應該 是 讀 一起 和 這 其他 警告 聲明 包含在我們截至2022年12月31日止年度的10-K表年度報告、隨後的10-Q表季度報告以及向美國證券交易委員會提交的8-K表最新報告中。任何前瞻性陳述僅代表其最初發表之日。除非有要求,否則我們沒有義務公開更新或修改任何前瞻性陳述,無論是由於新信息、未來事件、情況變化還是其他原因 法律。
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
聯繫人:
克雷森多通訊有限責任公司
大衛·沃爾德曼/亞歷山德拉·席爾特
電話:212-671-1020
電子郵件:ADIL@crescendo-ir.com